-+ 0.00%
-+ 0.00%
-+ 0.00%
Dong-A Socio Holdings corrects subsidiary on KRW 7.54 billion drug contract filing, extends disclosure hold to Oct. 7, 2029
Share
Listen to the news
Dong-A Socio Holdings corrects subsidiary on KRW 7.54 billion drug contract filing, extends disclosure hold to Oct. 7, 2029
  • Dong-A Socio Holdings issued a correction to its April 20 disclosure on a subsidiary supply contract.
  • Subsidiary name was revised to BTGen from STGenBio.
  • Confidentiality hold deadline was extended to Oct. 7, 2029 under counterparty terms.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dong-A Socio Holdings Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20260930801114), on September 30, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending